公开(公告)号：US20160146836A1

公开(公告)日：2016-05-26

申请号：US15007840

申请日：2016-01-27

Applicant: Roche Diagnostics Operations, Inc. ,  The Governing Council of the University of Toronto

Inventor： Ursula-Henrike Wienhues-Thelen ,  Georg Hess ,  Dirk Block ,  Hendrik Huedig ,  Andrew Emili ,  Anthony Gramolini ,  Peter Liu ,  David MacLennan ,  Sara Arab

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/6887 ,  G01N2333/4712 ,  G01N2800/325

Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.

Abstract translation: 本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物CRYAB的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，该浓度选自 由利尿钠肽标记物，心肌肌钙蛋白标志物和炎症标志物组成的组，并且通过将对于CRYAB测定的浓度与对任选的一种或多种其它标记物测定的浓度与浓度 的这种标记物或这些标记物在参考群体中建立。 还公开了CRYAB作为评估心力衰竭的标记蛋白的用途，包括CRYAB的标记组合和用于测量CRYAB的试剂盒。

公开(公告)号：US20140193845A1

公开(公告)日：2014-07-10

申请号：US14180384

申请日：2014-02-14

Applicant: The Governing Council of the University of Toronto ,  Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Sara Arab ,  Dirk Block ,  Andrew Emili ,  Anthony Gramolini ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  David MacLennan

IPC: G01N33/566

CPC classification number: G01N33/566 ,  G01N33/6893 ,  G01N2800/325

Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Abstract translation: 公开了一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物SFRP-3的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，以及 通过比较在SFRP-3中确定的浓度和为任选的一种或多种其它标记确定的浓度与在参考群体中确定的该标志物或这些标记物的浓度进行比较来评估心力衰竭。 还公开了在评估心力衰竭中使用SFRP-3作为标记蛋白，包括SFRP-3的标记物组合和用于测量SFRP-3的试剂盒。

公开(公告)号：US11644472B2

公开(公告)日：2023-05-09

申请号：US16217612

申请日：2018-12-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Dirk Block ,  Johann Karl ,  Peter Kastner ,  Ursula-Henrike Wienhues-Thelen ,  Roberto Latini ,  Serge Masson ,  Andre Ziegler ,  Edelgard Kaiser ,  Stefan Palme ,  Markus Thomas ,  Simona Barlera

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6887 ,  G01N33/6893 ,  G01N2800/326

Abstract: A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.

公开(公告)号：US20220412991A1

公开(公告)日：2022-12-29

申请号：US17891458

申请日：2022-08-19

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

公开(公告)号：US11454634B2

公开(公告)日：2022-09-27

申请号：US15911699

申请日：2018-03-05

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

公开(公告)号：US11047866B2

公开(公告)日：2021-06-29

申请号：US16420385

申请日：2019-05-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

IPC: G01N33/53 ,  G01N33/68

Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.

公开(公告)号：US10234464B2

公开(公告)日：2019-03-19

申请号：US15054255

申请日：2016-02-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hans-Peter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

IPC: G01N33/50 ,  G01N33/68 ,  A61K31/40 ,  G01N33/62

Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

公开(公告)号：US20180313850A1

公开(公告)日：2018-11-01

申请号：US16027890

申请日：2018-07-05

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Julian Braz ,  Hans-Peter Brunner ,  James Creeden ,  Hans-Joerg Loyda ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

IPC: G01N33/68

CPC classification number: G01N33/6887 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/58 ,  G01N2800/325 ,  G01N2800/52

Abstract: The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.

公开(公告)号：US20170074892A1

公开(公告)日：2017-03-16

申请号：US15359674

申请日：2016-11-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

IPC: G01N33/68

CPC classification number: G01N33/6887 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4712 ,  G01N2333/4737 ,  G01N2333/4745 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2800/326 ,  G01N2800/52

Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

公开(公告)号：US20170010283A1

公开(公告)日：2017-01-12

申请号：US15274533

申请日：2016-09-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/6887 ,  G01N2333/47 ,  G01N2800/325

Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract translation: 本发明涉及一种用于诊断和/或分级舒张功能障碍或与舒张功能障碍相关的至少一种结构或功能异常的方法。 该方法包括测量患有心力衰竭的患者中IGFBP7（胰岛素样生长因子结合蛋白7）的水平和任选地至少一个其他标记物的水平，并将该水平与参考水平进行比较。 进一步设想的是监测患有心力衰竭的患者的舒张功能的方法。 本发明还包括适用于实施本发明方法的试剂盒和装置。